YC-1: Soluble Guanylyl Cyclase Activator & HIF-1α Inhibitor in Cancer Research

Executive Summary: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol, available as SKU B7641 from APExBIO, acts as a soluble guanylyl cyclase (sGC) activator and a potent inhibitor of hypoxia-inducible factor-1α (HIF-1α) [product spec]. It inhibits hypoxia-induced HIF-1 transcriptional activity with an IC₅₀ of 1.2 μM in vitro, impacting tumor growth, survival, and angiogenesis [Llamab 2023]. YC-1 is highly soluble in DMSO (≥30.4 mg/mL) and ethanol (≥16.2 mg/mL) but insoluble in water, supporting diverse experimental workflows. It demonstrates reproducible tumor inhibition and cGMP pathway activation in preclinical models (Inan et al., 2024). The B7641 kit is supplied at ≥98% purity, with optimal performance under room temperature storage, and is not intended for diagnostic or therapeutic use [FlunarizineLab].

Biological Rationale

Hypoxia is a hallmark of solid tumors, driving aggressive growth and metastasis. Under low oxygen conditions, HIF-1α accumulates and activates genes critical for tumor adaptation, angiogenesis, and survival. Targeting hypoxia signaling pathways, including HIF-1α, is central to current cancer biology and drug discovery efforts. The cGMP pathway, modulated by soluble guanylyl cyclase (sGC), also influences vascular tone, platelet aggregation, and cellular apoptosis [Llamab 2023]. YC-1 uniquely addresses both axes—directly inhibiting HIF-1α and activating sGC—making it a valuable probe for dissecting tumor microenvironment adaptation and vascular homeostasis [TofacitinibBiz].

Mechanism of Action of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

YC-1 operates via two principal mechanisms:

• HIF-1α Inhibition: YC-1 suppresses HIF-1α by blocking its post-transcriptional accumulation, disrupting transcriptional activation of hypoxia-responsive genes (e.g., VEGF, GLUT1). This effect is oxygen-dependent and not a consequence of general cytotoxicity [3x-Flag-Peptide].
• sGC Activation: As a direct sGC activator, YC-1 increases intracellular cyclic GMP (cGMP) levels. This leads to smooth muscle relaxation, inhibition of platelet aggregation, and modulation of vascular tone [APExBIO].

These dual effects allow YC-1 to inhibit tumor angiogenesis while also providing potential benefits in circulatory disorders.

Evidence & Benchmarks

• YC-1 inhibits hypoxia-induced HIF-1 transcriptional activity with an IC₅₀ of 1.2 μM in HeLa cells under 1% O₂ conditions (APExBIO, product page).
• In vivo, YC-1 reduces tumor size and vascularization in mouse xenograft models; treated tumors show decreased HIF-1α and VEGF expression (TofacitinibBiz, article).
• YC-1 increases cGMP levels in vascular tissue, resulting in measurable vasorelaxation and platelet aggregation inhibition in vitro (Llamab, article).
• Compared to ω-agatoxin IVA (a P/Q-type calcium channel blocker), YC-1 exerts antitumor effects via hypoxia and cGMP pathways rather than direct neuroprotective or anticonvulsant actions (Inan et al., DOI).
• APExBIO’s B7641 kit delivers ≥98% purity, validated for cell-based and in vivo assays, streamlining reproducible hypoxia pathway research (FlunarizineLab).

Applications, Limits & Misconceptions

YC-1 is widely deployed in oncology, vascular biology, and hypoxia signaling studies. Its use cases include:

• Dissecting HIF-1α target gene regulation under hypoxic conditions.
• Evaluating tumor angiogenesis inhibition and apoptosis induction.
• Studying cGMP-dependent signaling in vascular tone and platelet function.

For an expanded comparison of cell-based assay optimization, see this guide, which details best practices and data interpretation strategies. This article extends those findings by providing molecular benchmarks and direct evidence links.

Common Pitfalls or Misconceptions

• Not a direct neuroprotective agent: YC-1 does not act as a P/Q-type calcium channel blocker and is not indicated for epilepsy models, unlike ω-agatoxin IVA (Inan et al., 2024).
• Water insolubility: YC-1 is insoluble in water; improper solvent selection can result in precipitation or poor bioavailability (APExBIO).
• Short-term solution stability: DMSO/ethanol solutions should be used promptly; long-term storage leads to degradation.
• Not for diagnostic or therapeutic use: YC-1 is strictly for research purposes and is not approved for clinical applications.
• Oxygen dependency: HIF-1α inhibition by YC-1 is effective under hypoxia but negligible in normoxic conditions.

Workflow Integration & Parameters

YC-1 (SKU B7641) from APExBIO is supplied as a crystalline solid. It should be dissolved in DMSO (≥30.4 mg/mL) or ethanol (≥16.2 mg/mL) immediately before use. Avoid water as a solvent. Typical working concentrations in cell-based assays range from 0.3–10 μM, with 1.2 μM as a benchmark for HIF-1 inhibition in hypoxia-adapted HeLa cells. For in vivo studies, dosages should be titrated based on animal model and desired pathway modulation. Solutions should be stored at room temperature and protected from light; use within a few hours. For cell proliferation and hypoxia pathway modulation, see Optimizing Cell-Based Assays with YC-1—this article clarifies molecular targets and best practices, extending that workflow guide.

For a review of dual sGC/HIF-1α modulation in cancer biology, see YC-1: Soluble Guanylyl Cyclase Activator for Cancer & Hypoxia. This article updates those findings with new benchmarks and mechanistic details.

Conclusion & Outlook

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol offers dual modulation of hypoxia and cGMP pathways, enabling robust investigation of tumor biology, angiogenesis, and apoptosis. Its high purity, validated activity, and solubility profile make it a preferred tool for advanced cancer and vascular research. APExBIO’s B7641 kit supports reproducible results across cell-based and animal models. While not suitable for neuroprotection or direct anticonvulsant applications, YC-1 remains a cornerstone in oxygen-sensing and signal transduction research. For full specifications and ordering, visit the YC-1 product page.